Houlihan Lokey Advises Impladent
Houlihan Lokey is pleased to announce that Impladent Ltd. has been acquired by Solmetex, LLC, a portfolio company of Avista Capital Partners (Avista). This transaction closed on June 1, 2023.
Solmetex, the dental industry's leading provider of dental waterline products and modern isolation solutions, announced that it has acquired Impladent Ltd., a provider of a broad range of innovative and affordable regenerative materials, including bone grafts and resorbable membranes used in dental extraction procedures. Impladent brings nearly 40 years of excellence and leadership in regenerative dental solutions, and its products are highly regarded by dentists for their efficacy and ease of use. Impladent’s flagship product, the OsteoGen® plug, is a one-step solution for socket preservation with the need for a membrane. As part of the Solmetex platform, Impladent will continue to expand and strengthen its ability to develop and market innovative products.
Solmetex is the largest closed-loop dental amalgam waste compliance service provider in North America and provides a variety of dental consumables and equipment to the dental market with a focus on the dental waterline, infection control, and modern dental isolation technology. The company’s NXT Hg5® series of amalgam separators and its recycling program, which treat dental wastewater, are highly regarded as the best solution for regulatory compliance. Solmetex is widely recognized as the single trusted source for comprehensive environmental solutions for dental waste needs. The combination with Impladent creates a diversified dental company with a strong portfolio of leading products across dental waterline treatment, modern dental isolation, and regenerative biomaterials. The combined company will continue its commitment to strengthen and expand partnerships built with individual dental practices and dental service organizations across the U.S. and global dental markets.
Founded in 2005, Avista Capital is a leading New York-based private equity firm with more than $8 billion invested in over 40 growth-oriented healthcare businesses globally. Avista partners with businesses that feature strong management teams, stable cash flows, and robust growth prospects—targeting product and technology businesses with clear scale potential across six sub-sectors experiencing strong tailwinds.
This transaction further strengthens and highlights Houlihan Lokey’s continued leadership in the medical technology industry. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the country. In 2022, the group closed 37 transactions and was ranked by Refinitiv as the No. 1 advisor for U.S. and global healthcare M&A transactions under $1 billion*.
Houlihan Lokey served as the exclusive financial advisor to Impladent.
*Excludes accounting firms and brokers.